Ligand News and Research

RSS

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

Alpha arrestins may play a role in cell signaling that is crucial to new drug development

A newly found understanding of receptor signaling may have revealed a better way to design drugs. A study from Nationwide Children's Hospital suggests that a newly identified group of proteins, alpha arrestins, may play a role in cell signaling that is crucial to new drug development.

11 Dec 2012

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Celldex to present results from CDX-301 Phase 1 study in healthy volunteers

Celldex Therapeutics, Inc. today announced an upcoming data presentation at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012.

6 Nov 2012

$Denosumab gives FREEDOM to heal fractures$

Denosumab gives FREEDOM to heal fractures

Results from the FREEDOM trial indicate that fracture healing is not impaired in women with osteoporosis who use the antiresorptive therapy denosumab.

2 Nov 2012

TSRI scientists to study structural rules that govern nuclear receptors

A consortium of scientists from both campuses of The Scripps Research Institute (TSRI) has been awarded $2.7 million from the National Institute of General Medical Sciences of the National Institutes of Health to study the structural rules that govern a large superfamily of proteins that help regulate critical functions such as reproduction, development and metabolism.

24 Oct 2012

Austrian researchers receive $7.4 million award to verify new breast cancer pathways

The innovator's award recognises Josef Penninger's work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.

23 Oct 2012

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Ligand Pharmaceuticals Incorporated today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.

22 Oct 2012

New approach to prevention of breast cancer wins $7.4M award

A new approach to possible future prevention of breast cancer and slowing the spread of tumours has won Austrian researcher Josef Penninger, director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, a $7.4 million innovator's award to continue his research, from the USA's Congressionally Directed Medical Research Program.

22 Oct 2012

Experts blaze TRAIL for pulmonary arterial hypertension therapy

Researchers have shown that the cell signaling molecule tumor necrosis factor-related apoptosis-inducing ligand may be a potential therapeutic target for pulmonary arterial hypertension.

16 Oct 2012

Pioneering research paves way for new treatments for pulmonary arterial hypertension

Pioneering research conducted by the University of Sheffield is paving the way for new treatments which could benefit patients suffering from the fatal lung disease pulmonary arterial hypertension (PAH).

15 Oct 2012

First picture of interaction between leptin and its receptor

Researchers at the University of Michigan have determined how the hormone leptin, an important regulator of metabolism and body weight, interacts with a key receptor in the brain.

12 Oct 2012

New screening method may lead to more efficient RNA drug development

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new method of screening more than three million combinations of interactions between RNA and small molecules to identify the best targets on RNA as well as the most promising potential drug compounds.

10 Oct 2012

Anesthetics and protein interactions: an interview with José A. Fernández

For a long time there was a controversy about how anesthetics work. The large number of molecules that have anesthetic properties (from benzodiazepines to nitrous oxide) and their very different structures...

8 Oct 2012

Kaneka to launch new Protein A Chromatography Resin for purification of therapeutic antibodies

Kaneka Corporation on 19/09/2012, announces the launch of KANEKA KanCapA, a new Protein A Chromatography Resin for the purification of therapeutic antibodies.

8 Oct 2012

Autoimmune disease myasthenia gravis halted in mice

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response the disorder triggers in the body.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012